Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

This page shows the publications co-authored by Robert Glynn and Joshua Gagne.
Connection Strength

4.144
  1. Connolly JG, Glynn RJ, Schneeweiss S, Gagne JJ. Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiol Drug Saf. 2020 Jan 23.
    View in: PubMed
    Score: 0.243
  2. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 11; 42(11):1355-1363.
    View in: PubMed
    Score: 0.239
  3. Bohn J, Schneeweiss S, Glynn RJ, Toh S, Wyss R, Desai R, Gagne JJ. Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.
    View in: PubMed
    Score: 0.234
  4. Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ. A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Clin Pharmacol Ther. 2019 07; 106(1):238-244.
    View in: PubMed
    Score: 0.229
  5. Bykov K, Mittleman MA, Glynn RJ, Schneeweiss S, Gagne JJ. The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Epidemiology. 2019 03; 30(2):204-211.
    View in: PubMed
    Score: 0.228
  6. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019 05; 28(5):665-670.
    View in: PubMed
    Score: 0.228
  7. Krumme AA, Glynn RJ, Schneeweiss S, Choudhry NK, Tong AY, Gagne JJ. Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004684.
    View in: PubMed
    Score: 0.218
  8. Wang SV, Huybrechts KF, Fischer MA, Franklin JM, Glynn RJ, Schneeweiss S, Gagne JJ. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
    View in: PubMed
    Score: 0.212
  9. Krumme AA, Pawar A, Schneeweiss S, Glynn RJ, Choudhry NK, Kulldorff M, Ortiz AS, Avorn J, Gagne JJ. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
    View in: PubMed
    Score: 0.210
  10. Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Bates DW, Gagne JJ. Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf. 2017 10; 40(10):923-932.
    View in: PubMed
    Score: 0.207
  11. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
    View in: PubMed
    Score: 0.188
  12. Desai RJ, Glynn RJ, Wang S, Gagne JJ. Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. Am J Epidemiol. 2016 05 15; 183(10):949-57.
    View in: PubMed
    Score: 0.187
  13. Kumamaru H, Schneeweiss S, Glynn RJ, Setoguchi S, Gagne JJ. Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol. 2016; 13:5.
    View in: PubMed
    Score: 0.186
  14. Wangge G, Schneeweiss S, Glynn RJ, Gagne JJ. Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiol Drug Saf. 2016 07; 25(7):755-62.
    View in: PubMed
    Score: 0.182
  15. Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012 Jul; 92(1):80-6.
    View in: PubMed
    Score: 0.142
  16. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:138-47.
    View in: PubMed
    Score: 0.142
  17. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
    View in: PubMed
    Score: 0.140
  18. Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
    View in: PubMed
    Score: 0.139
  19. Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011 Dec 01; 174(11):1213-22.
    View in: PubMed
    Score: 0.137
  20. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011 Jul; 64(7):749-59.
    View in: PubMed
    Score: 0.130
  21. Wang SV, Kulldorff M, Glynn RJ, Gagne JJ, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.054
  22. Krumme AA, Glynn RJ, Schneeweiss S, Gagne JJ, Dougherty JS, Brill G, Choudhry NK. Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Aff (Millwood). 2018 01; 37(1):125-133.
    View in: PubMed
    Score: 0.053
  23. Yoshida K, Hernández-Díaz S, Solomon DH, Jackson JW, Gagne JJ, Glynn RJ, Franklin JM. Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology. 2017 05; 28(3):387-395.
    View in: PubMed
    Score: 0.050
  24. Wyss R, Hansen BB, Ellis AR, Gagne JJ, Desai RJ, Glynn RJ, Stürmer T. The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. Am J Epidemiol. 2017 05 01; 185(9):842-852.
    View in: PubMed
    Score: 0.050
  25. Kumamaru H, Gagne JJ, Glynn RJ, Setoguchi S, Schneeweiss S. Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. J Clin Epidemiol. 2016 08; 76:200-8.
    View in: PubMed
    Score: 0.046
  26. Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013 May; 24(3):375-8.
    View in: PubMed
    Score: 0.038
  27. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011 Dec; 90(6):777-90.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.